Biomarker tests are an emergent precision medicine tool that helps physicians determine the best course of treatment for an individual patient based on unique information provided by “biomarkers.” These biomarkers can include proteins and genes.
Finding the right treatment for patients with rheumatologic conditions can often be a lengthy and painful process of trial and error. Precision medicine tools can help rheumatologists and patients find a therapy that successfully manages their condition more quickly, helping to reduce health care expenditures, suffering, and improve overall health.
The Coalition of State Rheumatology Organizations (CSRO) supports legislation that requires insurance plans to cover biomarker testing if a test has met certain criteria validating its clinical utility. CSRO is a co-signatory of the American Cancer Society Action Network’s state policy principles to support access to biomarker testing.
Visit our Legislative Map Tool to read about legislation in your state. You can send letters in support of pending legislation and find educational materials.